|
Product complaint # (b)(4).Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Device was used for treatment, not diagnosis.Investigation summary: the complaint device was received and inspected.The complaint cannot be confirmed.It was observed that the electrode tip shows sings of activation.Saline residue was present in the suction tube.The electrode functionally testing was performed.The device was connected to a test generator and no default occurred.With a test wired footswitch, both ablation and coagulation modes were activated for 30 seconds.The electrode activated during this operation with no signs of interruptions.A device history record (dhr) review has been conducted to determine if there were any internal processing issues which would have contributed to the nature of the product complaint.Our results indicate that this batch of product was processed without incident; therefore, there is no evidence of manufacturing anomalies on the paperwork reviewed.At this point, no corrective action is required and no further action is warranted.However, depuy synthes mitek will continue to track any related complaints within this device family as a means of monitoring the extent with which this complaint is observed in the field.Device history lot: dhr review.Part number: 228305; supplier lot number: u1802175; qty of lot: 152; manufacturing date: 03-13-2018; release to warehouse date: 03-28-2018; expiration date: 01-31-2021; supplier: (b)(4).Manufacturing site: cardiff, uk.No ncrs were generated during production.Review of the device history record(s) showed that there were no issues during the manufacture of this product, and any subcomponents, which would contribute to this complaint condition.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.Udi: (b)(4).
|